Belite Bio (BLTE) Stifel 2026 Virtual Ophthalmology Forum summary

Lead programs and disease focus

• Developing an oral therapy, tinlarebant, for Stargardt disease and expanding into geographic atrophy (GA), both severe retinal conditions with high unmet need.

• Stargardt disease affects about 50,000 patients in the U.S., making it significantly more prevalent than other rare retinal dystrophies.

• Tinlarebant is positioned as the first potential therapy for Stargardt disease, with NDA submission to the FDA planned within a month and anticipated priority review in the first quarter of next year.

Mechanism of action and clinical rationale

• Tinlarebant is an oral compound that reduces retinol (vitamin A) delivery to the eye by binding RBP4, thereby decreasing toxic bisretinoid buildup that leads to photoreceptor degeneration.

• The drug’s mechanism is highly specific to the eye, offering a targeted approach distinct from complement inhibitors and other therapies.

• Dose selection was based on single and multiple ascending dose studies, with 5 mg daily shown to achieve target RBP4 reduction and a favorable safety profile.

Clinical trial results and endpoints

• The DRAGON phase III trial in Stargardt disease demonstrated a 36% therapeutic effect in slowing disease progression, significantly higher than effect sizes seen with injectables in GA.

• Key secondary endpoint (DAF) also showed a 34% treatment effect, confirming primary results; statistically significant effects were observed in both eyes.

• Lesion size measured by DDAF is the primary regulatory endpoint, with nomenclature differences between Stargardt and GA but similar underlying pathology.